Pericardial inflammation imaging to predict recurrent pericarditis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 3, single-center, prospective cohort study enrolling adults with a history of recurrent pericarditis. The study uses 18F-FDG PET/CT with CTA to measure pericardial inflammation and compares imaging biomarkers from PET/CT and cardiac MRI between patients who have recurrence and those who do not over a one-year follow-up. Researchers aim to develop practical imaging-based flags that identify high-risk patients who may benefit from targeted therapies. About 44 participants will be followed at the Ottawa Heart Institute to assess whether imaging signals correlate with relapse risk. The study is sponsored by the Ottawa Heart Institute Research Corporation and conducted at the University of Ottawa Heart Institute in Ottawa, Ontario.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. History of recurrent pericarditis\* (i.e. presentation of at lease 2nd episode of acute pericarditis).
2. Age \>/= 18 years
3. Given informed consent

   * standard definitions will be used to define an episode of pericarditis. Pericarditis will be diagnosed by using available published criteria, which includes typical pericardial chest pain, pericardial friction rubs, widespread ST segment elevation or PR-segment depression that was not previously reported and new or worsening pericardial effusion on echocardiography. A clinical diagnosis of acute pericarditis will be made when at least 3 of these criteria are present.

Exclusion Criteria:

1. severe valve disease requiring intervention
2. claustrophobia that precludes FDG/PET or CMR imaging
3. pregnancy (all women of child bearing potential will have a negative BHCG test)
4. breastfeeding
5. glomerular filtration rate (GFR) \<50 m/min/1.72m2

Where it's running

• University of Ottawa Heart Institute
  Ottawa, Ontario, Canada Recruiting

Study contacts

• Study coordinator: Kevin Boczar, MD
• Email: KBoczar@ottawaheart.ca
• Phone: 613-696-7083

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Heart@Home: Safe, at-home care for people with acute heart problems compared with hospital care

  This trial tests whether hospital-level care at home can safely and effectively treat adults with acute heart conditions who would normally be in the hospital.

  Recruiting Tel-Aviv Sourasky Medical Center · Tel Aviv · NCT07913152

• Camptodactyly–Arthropathy–Coxa Vara–Pericarditis (CACP) syndrome patient registry and genetic review

  This registry collects clinical and genetic information to better understand CACP syndrome in children with confirmed PRG4 mutations.

  Recruiting at 3 sites Meyer Children's Hospital IRCCS · Bari and 9 other locations · NCT07468461

• Transitioning people with recurrent pericarditis to KPL-387 monotherapy dosing and administration

  This trial will try switching people with well-controlled recurrent pericarditis from their current therapies to KPL-387 alone for up to 16 weeks to see if symptoms and inflammation stay controlled and the drug is tolerable.

  Recruiting at 48 sites Phase 2 Kiniksa Pharmaceuticals International, plc · Phoenix, Arizona and 47 other locations · NCT07288216

• Imaging in Inflammatory Heart Diseases linked to autoimmune disorders

  This study tests how well multimodality imaging (CMR, echocardiography, and PET) detects inflammation in people with suspected inflammatory heart or autoimmune rheumatic diseases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07077304

• KPL-387 for recurrent pericarditis

  This trial tests whether KPL-387 can control pain and inflammation and lower the chance of future attacks in people having an acute episode of recurrent pericarditis despite standard treatment.

  Recruiting at 65 sites Phase 2/3 Kiniksa Pharmaceuticals International, plc · Gilbert, Arizona and 66 other locations · NCT07010159

• National surveillance of myocarditis and pericarditis after mRNA COVID-19 vaccination

  This study is trying to see how mRNA COVID-19 vaccines might affect heart health by following patients who develop heart inflammation after getting vaccinated.

  Recruiting Cardiology Research UBC · Vancouver, British Columbia · NCT06103123

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.